Monoclonal Antibody A6H Targeting Dipeptidyl Peptidase IV (CD26)

Biomaterial Description

A6H is a murine monoclonal antibody originally developed for selective recognition of human renal cell carcinoma antigens. Subsequent proteomic analysis using LC-MS/MS identified its target as Dipeptidyl Peptidase IV (DPPIV/CD26)—a multifunctional membrane-bound glycoprotein involved in immune regulation, signal transduction, and tumor biology. A6H binds with high specificity to CD26 expressed on epithelial and select tumor cell surfaces, enabling both diagnostic and therapeutic applications.

This antibody has been validated across multiple tissue types and demonstrates restricted reactivity, making it a powerful tool for studying CD26-associated pathophysiology and for developing targeted interventions.

Applications

-Cancer Research: Identification and characterization of CD26-expressing tumors, especially renal cell carcinoma

-Immunology: Investigation of CD26’s role in T-cell activation and immune modulation

-Therapeutic Development: Potential targeting of CD26 for antibody-drug conjugates or immune checkpoint modulation

-Diagnostic Tool: Immunohistochemical detection of CD26 in tissue samples

-Flow Cytometry: Suitable for surface marker analysis of CD26-expressing cells

-Immunocytochemistry & Immunofluorescence: Validated for fixed cell imaging using methanol/acetone protocols

-ELISA: Compatible with indirect ELISA formats for quantifying CD26 expression

Advantages

-High Specificity: Selective binding to CD26 with minimal cross-reactivity

-Validated Target: Confirmed via LC-MS/MS and immunohistochemistry

-Versatile Utility: Applicable in oncology, immunology, and diagnostic workflows

-Restricted Tissue Reactivity: Enables focused analysis of CD26-expressing cell populations

Distributor Information

Non-Exclusive License available.